Breast Cancer - Treatment Options, Symptoms, Causes & Diagnosis from MedifocusHealth

Breast Cancer > What Your Doctor is Reading About Breast Cancer > Drug Therapy

Drug Therapy

1. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials.

Author: De Laurentiis M; Cancello G; D'Agostino D; Giuliano M; Giordano A; Montagna E; Lauria R; Forestieri V; Esposito A; Silvestro L; Pennacchio R; Criscitiello C; Montanino A; Limite G; Bianco AR; De Placido S;
Institution: Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica, Universita di Napoli Federico II, Napoli, Italy. delauren@unina.it
Journal: J Clin Oncol. 2008 Jan 1;26(1):44-53.
Abstract URL: Click here to view abstract

2. Trastuzumab use for metastatic breast cancer in pregnancy.

Author: Sekar R; Stone PR;
Institution: Department of Obstetrics and Gynecology, Faculty of Medical and Health Science, University of Auckland, Auckland, New Zealand. renukas@adhb.govt.nz
Journal: Obstet Gynecol. 2007 Aug;110(2 Pt 2):507-10.
Abstract URL: Click here to view abstract

3. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer.

Author: Chia SK; Speers CH; D'yachkova Y; Kang A; Malfair-Taylor S; Barnett J; Coldman A; Gelmon KA; O'reilly SE; Olivotto IA;
Institution: Division of Medical Oncology, British Columbia Cancer Agency and the University of British Columbia, Vancouver and Victoria, British Columbia, Canada. schia@bccancer.bc.ca
Journal: Cancer. 2007 Sep 1;110(5):973-9.
Abstract URL: Click here to view abstract

4. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.

Author: Piccart-Gebhart MJ; Burzykowski T; Buyse M; Sledge G; Carmichael J; Luck HJ; Mackey JR; Nabholtz JM; Paridaens R; Biganzoli L; Jassem J; Bontenbal M; Bonneterre J; Chan S; Basaran GA; Therasse P;
Institution: Institut Jules Bordet, 121 boulevard de Waterloo, 1000 Brussels, Belgium. martine.piccart@bordet.be
Journal: J Clin Oncol. 2008 Apr 20;26(12):1980-6.
Abstract URL: Click here to view abstract

5. Fulvestrant in heavily pre-treated patients with advanced breast cancer: results from a single compassionate use programme centre.

Author: Catania C; Ascione G; Adamoli L; De Pas T; Medici M; Franceschelli L; Verri E; Magni E; Sanna G; Torrisi R; Goldhirsch A; Nole F;
Institution: Unit for Medical Care, Division of Medical Oncology, European Institute of Oncology, 20141, Milan, Italy, chiara.catania@ieo.it.
Journal: Breast Cancer Res Treat. 2007 Jan 27;.
Abstract URL: Click here to view abstract

6. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.

Author: Gibson Lj; Dawson C; Lawrence Dj; Bliss J;
Institution
Journal: Cochrane Database Syst Rev. 2007 Jan 24;(1):CD003370.
Abstract URL: Click here to view abstract

7. A review of the use of trastuzumab (Herceptin(R)) plus vinorelbine in metastatic breast cancer.

Author: Chan A;
Institution: Mount Breast Group, Mount Hospital, Perth, Australia.
Journal: Ann Oncol. 2007 Jan 29;.
Abstract URL: Click here to view abstract

8. Efficacy of lower dose capecitabine in patients with metastatic breast cancer and factors influencing therapeutic response and outcome.

Author: Sezgin C; Kurt E; Evrensel T; Ozdemir N; Manavoglu O; Goker E;
Institution: Division of Medical Oncology, Department of Pathology, Ege University School of Medicine, Izmir, Turkey. canfeza.sezgin@ege.edu.tr
Journal: South Med J. 2007 Jan;100(1):27-32.
Abstract URL: Click here to view abstract

9. Preclinical and clinical studies on the use of platinum complexes for breast cancer treatment.

Author: Ott I; Gust R;
Institution: Institute of Pharmacy, Free University of Berlin, Konigin Luise Str. 2+4, 14195 Berlin, Germany.
Journal: Anticancer Agents Med Chem. 2007 Jan;7(1):95-110.
Abstract URL: Click here to view abstract

10. Continuing with letrozole offers greater benefits.

Author: Janicke F;
Institution: Breast Center, University Hospital Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany, jaenicke@uke.uni-hamburg.de.
Journal: J Cancer Res Clin Oncol. 2007 Jan 17;.
Abstract URL: Click here to view abstract

11. Early discontinuation of tamoxifen: a Lesson for oncologists.

Author: Barron TI; Connolly R; Bennett K; Feely J; Kennedy MJ;
Institution: Department of Pharmacology and Therapeutics, Trinity College Dublin, Trinity Centre for Health Sciences, St. James's Hospital, Dublin, Ireland.
Journal: Cancer. 2007 Jan 22;.
Abstract URL: Click here to view abstract

12. Use of adjuvant systemic therapy for early breast cancer among women 65 years of age and older.

Author: Balasubramanian BA; Gandhi SK; Demissie K; August DA; Kohler B; Osinubi OY; Rhoads GG;
Institution: Department of Family Medicine, University of Medicineand Dentistry of New Jersey, Robert Wood Johnson MedicalSchool, Somerset, NJ 08873, USA. balasuba@umdnj.edu
Journal: Cancer Control. 2007 Jan;14(1):63-8.
Abstract URL: Click here to view abstract

13. Do endocrine treatments for breast cancer have a negative impact on lipid profiles and cardiovascular risk in postmenopausal women?

Author: Lewis S;
Institution: Northwest Cardiovascular Institute, Portland, OR 97210, USA. sandral@nw-ci.com
Journal: Am Heart J. 2007 Feb;153(2):182-8.
Abstract URL: Click here to view abstract

14. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.

Author: Cuzick J; Ambroisine L; Davidson N; Jakesz R; Kaufmann M; Regan M; Sainsbury R;
Institution: Cancer Research UK Centre for Epidemiology, Mathematics and Statistics, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK. jack.cuzick@cancer.org.uk
Journal: Lancet. 2007 May 19;369(9574):1711-23.
Abstract URL: Click here to view abstract

15. Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme.

Author: Mlineritsch B; Psenak O; Mayer P; Moik M; Namberger K; Hauser-Kronberger C; Greil R;
Institution: III Medical Department with Haematology, Medical Oncology, Haemostaseology, Rheumatology and Infectious Disease, Paracelsus Private Medical University Salzburg, and Laboratory of Immunological and Molecular Cancer Research, Mullner Hauptstrasse 48, 5020 , Salzburg, Austria, r.greil@salk.at.
Journal: Breast Cancer Res Treat. 2007 Feb 13;.
Abstract URL: Click here to view abstract

16. Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers.

Author: Mazouni C; Kau SW; Frye D; Andre F; Kuerer H; Buchholz T; Symmans W; Anderson K; Hess K; Gonzalez-Angulo A; Hortobagyi G; Buzdar A; Pusztai L;
Institution: Department of Breast Medical Oncology.
Journal: Ann Oncol. 2007 Feb 10;.
Abstract URL: Click here to view abstract

17. Ovarian cancer risk in premenopausal and perimenopausal women treated with Tamoxifen: a case-control study.

Author: Swerdlow AJ; Jones ME;
Institution: 1Section of Epidemiology, Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK.
Journal: Br J Cancer. 2007 Feb 6;.
Abstract URL: Click here to view abstract

18. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.

Author: Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR; Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR;
Institution: Department of Medicine and Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA. dlh23@columbia.edu
Journal: J Natl Cancer Inst. 2007 Feb 7;99(3):196-205.
Abstract URL: Click here to view abstract

19. Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma : pooled analysis of 2 consecutive trials.

Author: Boccardo F; Rubagotti A; Aldrighetti D; Buzzi F; Cruciani G; Farris A; Mustacchi G; Porpiglia M; Schieppati G; Sismondi P;
Institution: University and National Cancer Research Institute, Genoa, Italy.
Journal: Cancer. 2007 Feb 12;.
Abstract URL: Click here to view abstract